Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Beam Therapeutics (BEAM) Operating Expenses (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Operating Expenses for 7 consecutive years, with -$251.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 24.43% to -$251.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$243.7 million, a 1542.24% decrease, with the full-year FY2025 number at -$243.7 million, down 1542.24% from a year prior.
  • Operating Expenses was -$251.0 million for Q4 2025 at Beam Therapeutics, down from -$248.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $340.4 million in Q3 2024 to a low of -$332.1 million in Q4 2024.
  • A 5-year average of $14.9 million and a median of $91.6 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: plummeted 323.86% in 2022, then surged 4867.83% in 2025.
  • Beam Therapeutics' Operating Expenses stood at $114.6 million in 2021, then tumbled by 323.86% to -$256.4 million in 2022, then decreased by 26.36% to -$324.0 million in 2023, then dropped by 2.48% to -$332.1 million in 2024, then rose by 24.43% to -$251.0 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Operating Expenses are -$251.0 million (Q4 2025), -$248.1 million (Q3 2025), and $128.6 million (Q2 2025).